Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. - Wikidata - awgldk - TriplyDB

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.

http://www.wikidata.org/entity/Q33957168

about

Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis Inhaled therapy in cystic fibrosis: agents, devices and regimens Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic Fibrosis Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy Tolerability and Pharmacokinetic Evaluation of Inhaled Dry Powder Tobramycin Free Base in Non-Cystic Fibrosis Bronchiectasis Patients The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review Clinical experimentation with aerosol antibiotics: current and future methods of administration.Inhaled antibiotics for lower airway infections.Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial.Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.Risk factors for chronic kidney disease in adults with cystic fibrosis.Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.Tackling the increasing complexity of CF care.Antibiotic and anti-inflammatory therapies for cystic fibrosis.Progress in cystic fibrosis and the CF Therapeutics Development Network Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review.Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection.Tobramycin inhalation powder: a review of its use in the treatment of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.Emerging drugs for cystic fibrosis.The PulmoSphere™ platform for pulmonary drug delivery.Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients.Aerosolized antibiotics in cystic fibrosis: an update.Inhaled liposomal amikacin.Efficacy and adverse effects of drugs used to treat adult cystic fibrosis.Use of inhaled tobramycin in cystic fibrosis.Tobramycin inhalation powder: an efficient and efficacious therapy for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis.Long-term safety and efficacy of tobramycin in the management of cystic fibrosis.Long-term safety of tobramycin inhalation powder in patients with cystic fibrosis: phase IV (ETOILES) study.Novel inhaled combined antibiotic formulations in the treatment of Pseudomonas aeruginosa airways infections in cystic fibrosis.Pulmonary drug delivery: a review on nanocarriers for antibacterial chemotherapy.Improving complex medical care while awaiting next-generation CFTR potentiators and correctors: The current pipeline of therapeutics.Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis.Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.

P2860

Q24188054-EAB6EF45-4218-4B35-A402-9AED8A9D6562 Q26797450-A9A5192D-424E-45BA-9616-A9836DC20E1C Q26822988-CEDAB1E8-7668-4FA4-92C8-431D59021D11 Q26829604-F833ED01-5422-4BCB-9936-5119434ECFE4 Q27014993-FEB20580-CAF0-49CC-BDC6-32F880BCC4DC Q28550641-6F2C2CF7-1A1A-414B-A451-97AC25E82142 Q30234649-B8DC1C12-C59D-48DB-B58E-9A7AFF069AC9 Q30448377-7D345B6E-7933-46E3-B499-795041FAE503 Q33640488-0B080BB8-ECBC-405C-8554-C9100BEF0FDF Q33861076-9353EB9A-1A4E-4316-ABF9-B001697474F7 Q33861117-DDE11EB2-8C25-4715-B7DC-839B32F776AD Q34297656-02320F3C-EF75-4279-A7F2-6F100C26D23C Q35682983-5A7C0E7C-2230-442C-B290-0A8C000FF1DE Q35801062-B5883B0A-1CCC-4C01-844C-3C13F4231261 Q36034488-81A4CFAE-6F0C-45B9-9C5C-2DF2959BDF2D Q37201467-9A7AF842-C423-4B6F-83E4-1311F5957F60 Q37209004-B3635046-4E5B-4566-87D3-74E6DB347347 Q37381499-9927B5AA-A730-4C3F-BD6B-0ECA46D2A0E4 Q37851986-3525B898-A494-4046-9D3A-F9019D114CD7 Q37940005-49960DE7-9C31-4B83-AD12-170DEB7D66B8 Q38037076-C3598E72-ECC1-46F8-9B07-039323FB0CF2 Q38094297-6CB8BC76-A128-4465-9ECB-3D97A2D74625 Q38099053-ECDBD0B4-88B2-4922-8A24-FBF739F32B9D Q38130513-B64A05BF-1273-497D-8171-E82B487FEBB0 Q38160206-5D81D022-F41E-44AE-B98C-5C5BD8557742 Q38183476-24881C85-4738-4E90-948E-B46EA4112619 Q38193170-28494FE6-1BF9-4176-BAD7-2396AB038D9A Q38193537-3B70FA99-C7F5-47D3-AB3D-7ACBA7A56B15 Q38212537-BBCE0129-6C9D-4320-AD17-A5DA2CEC31F5 Q38216555-B5808747-BF82-448B-9453-1A8868A74758 Q38325672-EE9C54BD-2D6C-488A-ABB0-D737D8A3EBD6 Q38332222-90AEC034-B8DA-433F-A0FC-4778FF6C4C3B Q38358856-AA7F7990-055C-45DE-B17D-0E23C85AF2B3 Q38384994-437F38E2-4BF6-4FB6-BCE5-C87E0BDF70A9 Q38386414-9949EFBB-9850-41EC-A421-9E415D08025E Q38447194-0BCC92E9-0444-4327-AF96-FE618F1E7B00 Q38552573-F2D9A739-036C-4B3C-B6E5-475EEC686F81 Q38579967-F59C9EF5-F929-4D7E-8638-5E9D5F95B2B3 Q38630919-541497AB-F2CF-4B48-BC27-2E9B97247201 Q38729352-4E57B07B-58EB-42A0-8743-EF644E8A1479

P2860

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.

http://www.wikidata.org/entity/Q33957168

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Tobramycin inhalation powder f ...... ic fibrosis: the EVOLVE trial.

@ast

Tobramycin inhalation powder f ...... ic fibrosis: the EVOLVE trial.

@en

type

label

Tobramycin inhalation powder f ...... ic fibrosis: the EVOLVE trial.

@ast

Tobramycin inhalation powder f ...... ic fibrosis: the EVOLVE trial.

@en

prefLabel

Tobramycin inhalation powder f ...... ic fibrosis: the EVOLVE trial.

@ast

Tobramycin inhalation powder f ...... ic fibrosis: the EVOLVE trial.

@en

P1433

Q33957168-7C39FFD6-7211-495A-A8C8-A5008A36A415

P1476

Q33957168-BC6AAB90-0277-4734-AFBE-E0D30169786F

P2093

Q33957168-1217A230-FA0F-4513-8DAD-5D874CCAEEC4

Q33957168-5ED398BA-A8D1-414D-9BD5-78EF9432F383

Q33957168-6724D302-BDD2-4652-8F2E-31D7E9455359

Q33957168-B5C55ECB-3E6D-4C66-A9D3-87940015418A

Q33957168-BF506FD3-5E2E-4D6C-A002-EB11ED7CD058

Q33957168-FBA9F196-2A0E-440E-80AB-22099E403BA1

P2860

Q33957168-015E0F92-5C0B-4216-ABD6-102BAA8F119C

Q33957168-09E8317B-01D8-4C0A-91D5-DBA1CBE4C3F4

Q33957168-1E7AB6C4-2680-4319-8BD0-CC4F60DCEB45

Q33957168-31FEA7E7-1D09-4D0E-B416-6D64378483A8

Q33957168-3EAAAC32-E903-417C-886C-80D410ABEB8E

Q33957168-40D6444C-7701-4229-8B14-A6EA56010B31

Q33957168-58C6E240-B8C1-4585-BF93-D20621144B4D

Q33957168-59989599-398E-41B1-BEB5-ACE9A3423DA7

Q33957168-5AE76AA1-1261-459C-BF83-FF3BA074B662

Q33957168-5E1EEF0B-268D-4F13-ACE7-610D6EE51FC6

P304

Q33957168-29EE299B-117D-4F59-8DC1-D0259B91A298

P31

Q33957168-A27796BC-1539-4577-BB40-9674C369BDDC

P356

Q33957168-790CEC8D-B60E-4C19-81D3-1D46CE9A3536

P433

Q33957168-1DDECBF4-69F0-4266-BBF7-CA76F6D76DB7

P478

Q33957168-CC05588C-4440-4C63-84D9-C04532999B98

P577

Q33957168-8B25BCA5-F11E-4949-9B08-30189F55F9A1

P5875

Q33957168-0777B74A-1980-494C-BF69-9A5649644B4F

P698

Q33957168-7D5D48D5-4B3B-4DA5-9295-39EEDBC97BF4

P921

Q33957168-17F2A9AD-2348-4AD3-89F9-C37DD9F67ABF

P932

Q33957168-81F6DCCA-69F3-465C-9C63-49C68DBAC318

P356

P1433

Pediatric Pulmonology

P1476

Tobramycin inhalation powder f ...... ic fibrosis: the EVOLVE trial.

@en

P2093

David E Geller

http://www.w3.org/2001/XMLSchema#string

Florian Brockhaus

http://www.w3.org/2001/XMLSchema#string

Gerhild Angyalosi

http://www.w3.org/2001/XMLSchema#string

Jie Zhang

http://www.w3.org/2001/XMLSchema#string

Michael W Konstan

http://www.w3.org/2001/XMLSchema#string

Predrag Minić

http://www.w3.org/2001/XMLSchema#string

P2860

Nebulised anti-pseudomonal antibiotics for cystic fibrosis

Standardization of Spirometry, 1994 Update. American Thoracic Society

Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy

Changes in the normal maximal expiratory flow-volume curve with growth and aging.

Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.

Pathophysiology and management of pulmonary infections in cystic fibrosis.

Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease.

Early intervention and prevention of lung disease in cystic fibrosis: a European consensus.

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Bugs, biofilms, and resistance in cystic fibrosis.

P304

230-238

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PPUL.21356

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P577

2010-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47511470

http://www.w3.org/2001/XMLSchema#string

P698

20963831

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

4112574

http://www.w3.org/2001/XMLSchema#string